Publication date: May 01, 2019
-CVN424’s excellent safety profile helps validate Cerevance’s approach to CNS target selection and drug discovery,” said David H. Margolin, MD, PhD, Senior Vice President for Clinical and Translational Medicine at Cerevance.
-CVN424 acts through a target that is selectively expressed by neurons important in controlling movement and was engineered to achieve excellent CNS penetration with minimal effects on other organs. “
Beyond CVN424, we look forward to advancing a broad pipeline of therapies acting on targets that have not yet been explored for the treatment of CNS disorders. “
|disease||MESH||central nervous system diseases|
- FDA to Review Istradefylline NDA for Parkinson Disease Again
- Nanodelivery of therapeutic agents in Parkinson’s disease.
- Data in Parkinson’s Disease Model in Non-human Primates Demonstrate Reversal of Cognitive Deficits with Novel NMDA Receptor Modulator, NYX-458
- Dopaminergic urethral closure mechanisms in a rat model of Parkinson’s disease.